7 results
Antiplatelet Conversion - Switching Between P2Y12 Inhibitors
Oral P2Y12 inhibitors vary in potency and pharmacokinetic and dynamic
Antiplatelet Conversion ... during hospitalization ... Drug interactions ... ticagrelor #prasugrel #pharmacology ... #Cangrelor
Angiotensin-Converting Enzyme Inhibitors - Inhibit the conversion of AngI to AngII
 • Captopril, Lisinopril, Enalapril, Benazepril,
- Inhibit the conversion ... Receptor Blockers ... - Block AT1 receptors ... #ACEis #ARBs #pharmacology ... #medications #drugs
Angiotensin Receptor Blockers 
Recommended Dose Conversions 

Valsartan 
Irbesartan 
Losartan 
Olmesartan 
Telmisartan 
Candesartan 
Azilsartan 
Eprosartan 

A few
Angiotensin Receptor ... of another drug ... #ARB #Conversion ... #Table #Dosing ... #Pharmacology #Dose
ANGIOTENSIN II RECEPTOR ANTAGONIST (ARB) DOSING:
TOOL FOR SWITCHING BETWEEN AGENTS IN CANADA
The information provided is intended
ANGIOTENSIN II RECEPTOR ... ) DOSING: TOOL ... Doses should be ... #ARB #AngiotensinII ... #Conversion #Switching
Cangrelor - Pharmacology
Cangrelor (Kengreal) is a parenteral analogue of adenosine triphosphate
Cangrelor binds reversibly to the platelet
Cangrelor - Pharmacology ... platelet P2Y12 receptor ... an oral P2Y12 inhibitor ... , are prodrugs, ... such that the drug
Antiplatelet Conversion - Switching Between Oral P2Y12 Inhibitors
A, Switching between oral agents in the acute/early phase.
Antiplatelet Conversion ... of patients who are ... of a given drug ... the timing and dosing ... ticagrelor #prasugrel #pharmacology
Management of Anthracyclines and HER2 Antagonist Cardiotoxicity
Anthracyclines cause cardiomyopathy:
 ✖ Reduction in left ventricular ejection fraction
failure with renin-angiotensin-aldosterone ... system (RAAS) inhibitor ... mineralocorticoid receptor ... every 3 months during ... cardiology #oncology #pharmacology